NASDAQ: $RDHL The landscape of Crohn’s disease (CD) treatment may be on the cusp of a significant shift. RedHill Biopharma Ltd. recently announced promising in vitro testing results for RHB-204, a next-generation oral formulation that represents a targeted therapeutic approach to the condition. By focusing on Mycobacterium avium subspecies paratuberculosis (MAP), RedHill is pursuing a strategy…